FTC K-Dur Suit Would Allow Andrx Generic Launch; FDA Could Act First
• By The Pink Sheet
Andrx believes it may be able to launch a generic version of Schering-Plough's K-Dur during the second half of the year regardless of the outcome of the Federal Trade Commission's administrative action over patent settlements involving K-Dur.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights